# ENDRA Life Sciences Inc. (NDRA)

Source: https://www.quantisnow.com/company/NDRA
Generated: 2026-11-18T16:46:22.895Z

- Ticker: NDRA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus
- IPO year: 2017
- SEC CIK: 0001681682
- Website: endrainc.com

## About

ENDRA Life Sciences Inc. develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion. The company also offers diagnostic imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound that allow physicians to look inside a person's body to guide treatment or gather information about medical conditions, such as broken bones, cancers, signs of heart disease, or internal bleeding. The company has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

## Latest NDRA news and filings

- 2026-11-16 22:04 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-results-of-6794811)
- 2026-11-16 21:44 UTC [Earnings] [ENDRA Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/endra-life-sciences-reports-third-quarter-2026-financial-results-and-6794688)
- 2026-11-10 12:54 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-endra-life-sciences-inc-6782917)
- 2026-10-01 21:21 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6733000)
- 2026-10-01 21:18 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-entry-into-6732980)
- 2026-09-25 21:09 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6726718)
- 2026-09-14 21:15 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6714899)
- 2026-08-17 20:07 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6684957)
- 2026-08-17 20:05 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-results-of-6684925)
- 2026-08-04 12:00 UTC [Conference Announcement] [ASP Isotopes Issues Letter to Shareholders](https://www.quantisnow.com/insight/asp-isotopes-issues-letter-to-shareholders-6661151)
- 2026-07-17 12:20 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6640572)
- 2026-07-17 12:00 UTC [Market Insight] [Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company](https://www.quantisnow.com/insight/join-the-live-investor-webinar-for-noble-africa-the-proposed-6640524)
- 2026-07-09 10:08 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-other-events-6632244)
- 2026-06-30 01:29 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-endra-life-sciences-6619675)
- 2026-06-26 10:16 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6616656)
- 2026-06-26 10:10 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Changes in Control of Registrant, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-entry-into-6616645)
- 2026-06-25 22:24 UTC [SEC Form 144] [SEC Form 144 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-endra-life-sciences-inc-6616447)
- 2026-06-25 13:38 UTC [SEC Form 425] [SEC Form 425 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-endra-life-sciences-inc-6615427)
- 2026-06-25 13:37 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-regulation-fd-6615424)
- 2026-05-28 10:07 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-entry-into-6575941)
- 2026-05-26 20:59 UTC [SEC Form RW filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-endra-life-sciences-inc-6572857)
- 2026-05-18 12:00 UTC [ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/endra-life-sciences-reports-first-quarter-2026-financial-results-and-6559164)
- 2026-05-15 20:14 UTC [SEC Form S-8] [SEC Form S-8 filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-endra-life-sciences-inc-6557452)
- 2026-05-15 20:01 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-endra-life-sciences-inc-6556995)
- 2026-05-14 12:00 UTC [ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility](https://www.quantisnow.com/insight/endra-life-sciences-reports-multi-site-validation-of-taeus-liver-device-6552486)
- 2026-04-21 12:00 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-notice-of-6507761)
- 2026-03-31 21:10 UTC [SEC Form 10-K] [SEC Form 10-K filed by ENDRA Life Sciences Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-endra-life-sciences-inc-6479915)
- 2026-03-31 20:29 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-results-of-6479482)
- 2026-03-31 20:05 UTC [ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-6478916)
- 2026-03-25 13:21 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-costs-associated-6468456)
- 2026-03-25 12:00 UTC [ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value](https://www.quantisnow.com/insight/endra-life-sciences-initiates-review-of-strategic-alternatives-to-maximize-6468160)
- 2026-03-05 02:48 UTC [SEC Form 4] [Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-tokman-alexander-y-was-granted-26921-shares-6431133)
- 2026-03-05 02:48 UTC [SEC Form 4] [Chief Financial Officer Jacroux Richard was granted 13,461 shares, increasing direct ownership by 67% to 33,461 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-jacroux-richard-was-granted-13461-shares-increasing-6431132)
- 2026-02-26 13:00 UTC [ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care](https://www.quantisnow.com/insight/endras-taeus-liver-device-demonstrates-high-level-consistency-in-clinical-study-6414994)
- 2026-01-24 00:44 UTC [SEC Form 4] [Director Digiandomenico Anthony was granted 60,324 shares, increasing direct ownership by 79% to 136,589 units (SEC Form 4)](https://www.quantisnow.com/insight/director-digiandomenico-anthony-was-granted-60324-shares-increasing-direct-ownership-6359803)
- 2026-01-24 00:43 UTC [SEC Form 4] [Director Harsh Michael was granted 60,324 shares, increasing direct ownership by 1,120% to 65,710 units (SEC Form 4)](https://www.quantisnow.com/insight/director-harsh-michael-was-granted-60324-shares-increasing-direct-ownership-6359801)
- 2026-01-24 00:43 UTC [SEC Form 4] [Chief Financial Officer Jacroux Richard was granted 20,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-jacroux-richard-was-granted-20000-shares-sec-6359800)
- 2026-01-24 00:43 UTC [SEC Form 4] [Director Basenese Lou was granted 60,324 shares, increasing direct ownership by 1,120% to 65,709 units (SEC Form 4)](https://www.quantisnow.com/insight/director-basenese-lou-was-granted-60324-shares-increasing-direct-ownership-6359799)
- 2026-01-24 00:42 UTC [SEC Form 4] [Chief Executive Officer Tokman Alexander Y was granted 75,000 shares, increasing direct ownership by 1,500,000% to 75,005 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-tokman-alexander-y-was-granted-75000-shares-6359797)
- 2025-12-13 01:31 UTC [SEC Form 8-K] [ENDRA Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/endra-life-sciences-inc-filed-sec-form-8-k-leadership-update-6315093)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/NDRA
- Earnings history: https://www.quantisnow.com/earnings/NDRA
- Dividend history: https://www.quantisnow.com/dividends/NDRA
- Insider transactions: https://www.quantisnow.com/insiders/NDRA
- Options chain: https://www.quantisnow.com/options/NDRA
- SEC 8-K filings only: https://www.quantisnow.com/company/NDRA/8-k
- RSS and alerts for NDRA: https://www.quantisnow.com/docs/rss-feeds.md
